fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:
Friday, January 14, 2022

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on January 10, 2022. The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an…

Read More »

Thursday, January 13, 2022

PacBio Names Lara Toerien as Vice President and General Manager for the Americas

Industry Veteran Will Lead Company’s Commercial Growth Strategy in Americas Region MENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the company’s Americas region. Lara will be responsible for leading and developing PacBio’s commercial organization within North and South America while furthering its growth and market presence throughout the region. Lara is a genomics industry veteran with 25 years of experience in commercial roles of increasing responsibility. She most recently served as Senior Regional Sales Director, Northeast…

Read More »

Tuesday, January 11, 2022

PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China

New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China Berry Genomics to purchase at least 50 instruments at product launch MENLO PARK, Calif. and BEIJING, Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, and Berry Genomics, a leading company in clinical genomics and life science in China, today announced a collaboration to provide PacBio long read sequencing technology to the Chinese clinical market. Under the new agreement, PacBio will develop its first long read desktop sequencing platform with funding…

Read More »

Tuesday, January 11, 2022

PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology

Pilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencing MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics England to study PacBio’s technology for identifying genetic variants in unexplained rare disease cases. Genomics England was initially created to deliver the 100,000 Genomes Project – the largest whole genome sequencing disease cohort of cancer and rare disease participants in the National Health Service (NHS). The study will re-sequence a selection of…

Read More »

Tuesday, January 11, 2022

PacBio and Google Collaborate to Use Machine Learning to Optimize Long-Read Sequencing Data Analysis

Initial proof-of-concept work suggests strong potential to further improve PacBio’s highly accurate HiFi Sequencing with Google deep learning technologies MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced a research collaboration with Google. Under the terms of the collaboration, PacBio will explore the use of Google’s genomic analysis, machine learning and algorithm development tools to further improve PacBio’s already highly accurate variant calls for HiFi sequencing runs, unlocking more insights from PacBio sequencing data. The collaboration builds on previous research from PacBio and Google. A recent…

Read More »

Tuesday, January 11, 2022

PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available. Business Updates: Expect preliminary fourth quarter revenue of approximately $36.0 million, representing an increase of approximately 33% compared with $27.1 million for the fourth quarter of 2020. As a result, preliminary annual 2021 revenue is expected to be $130.5 million, representing…

Read More »

Friday, January 7, 2022

Radboud University Medical Center Increases HiFi Sequencing Capacity with PacBio’s Sequel IIe

Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughput MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands will increase their SMRT sequencing capacity with the addition of two new PacBio Sequel IIe Systems. Radboudumc has been using PacBio long-read technology for the last three years to identify hidden variants that cause rare diseases. “Over time we have adapted our workflows to use our Sequel systems in rare disease cases and…

Read More »

Thursday, January 6, 2022

Azenta Life Sciences Expands Fleet of PacBio HiFi Sequencing Systems

PacBio’s Sequel IIe devices will support genomic researchers around the world MENLO PARK, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB) today announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ. The deal will increase PacBio’s HiFi sequencing platforms across Azenta’s newly combined company and support Azenta’s mission to enable life science companies to deliver impactful breakthroughs and therapies to market faster. PacBio’s HiFi sequencing technology uniquely combines the benefits of high accuracy with long read lengths, providing a comprehensive view of genomes and transcriptomes to scientists tackling complex genetic challenges.…

Read More »

Wednesday, January 5, 2022

PacBio and Care4Rare Consortium Collaborate on Rare Disease Research Study

The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease cases MENLO PARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) — PacBio, a leading provider of high-quality, long-read sequencing platforms, and the Care4Rare Canada Consortium (Care4Rare) announce today they are collaborating to study some of the most complex unexplained rare disease cases within Canada. Care4Rare, led out of the CHEO Research Institute affiliated with the University of Ottawa, includes 21 academic sites across Canada and is recognized internationally as a pioneer in the field of genomics and personalized medicine. “Care4Rare launched the C4R-SOLVE project…

Read More »

Tuesday, January 4, 2022

PacBio to Present at Upcoming Investor Conference

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — PacBio announced today that its executives will be speaking virtually at the following investor conference: 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm Eastern Time (9:00 am Pacific Time) The live webcast can be accessed at the company’s investors page at https://investor.pacificbiosciences.com . A replay of the webcast will be available for at least 30 days following the presentation. About PacBio Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule,…

Read More »

Tuesday, December 28, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response MENLO PARK, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced and captured the entire genome of the SARS-CoV-2 Omicron variant lineage. The solution gives researchers around the globe a powerful tool to access complete genomic information on Omicron, without gaps in sequencing information that can result from mutations that occur along the SARS-CoV-2 virus genome. “Detecting the Omicron…

Read More »

Tuesday, December 7, 2021

PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseases

Collaboration aims to identify variants not easily detectible by short-read sequencing, increasing diagnostic yield in rare disease patients MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and the UCLA Institute for Precision Health and David Geffen School of Medicine at UCLA have formed a research collaboration to further identify the causes of rare diseases. The study will leverage PacBio’s HiFi long-read sequencing technology for whole genome sequencing (WGS) to look at undiagnosed pediatric rare disease patients who have already been sequenced with short-read technology. Dr. Stanley Nelson,…

Read More »

Friday, December 3, 2021

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on November 29, 2021. The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an…

Read More »

Tuesday, November 30, 2021

PacBio Names Jason Kang as Vice President and General Manager for Asia-Pacific Region

Strategic hire will expand Company’s commercial presence in key geography MENLO PARK, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing platforms, welcomes Jason Kang as Vice President and General Manager for the company’s Asia-Pacific region. Jason will be responsible for leading and developing PacBio’s commercial team in Asia-Pacific as the company continues to expand its reach in the region to support rapidly growing demand for HiFi sequencing. Kang brings more than 25 years of global experience in the genomics industry to PacBio, having led Illumina’s Korean commercial operations for six years before…

Read More »

Friday, November 19, 2021

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on November 15, 2021. The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an…

Read More »

1 2 3 20

Subscribe for blog updates:

Archives

Search

Categories

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, January 14, 2022

Stay
Current

Visit our blog »